cyrilzakka/clinical-trials huggingface dataset:
Platelet Enriched Plasma for Treatment of Interstitial Cystitis

A prospective randomized trial will be conducted aiming at evaluation the efficacy and safety of platelet enriched plasma for management of bladder pain syndrome .


Eligibility Criteria:
Inclusion Criteria:

* Patients with a diagnosis of interstitial cystitis/ Bladder painful Syndrome for more than 3 months will be enrolled

Exclusion Criteria:

* Patients with Anemia, blood disorders, history of pelvic irradiation, pelvic malignancy, and active urinary tract infection unless treated, vesical stone, gynecological disorders e.g. uterine fibroid and neurological disorders will be excluded. Patients less than 18 years old will not be allowed to participate.
Extracorporeal Flow Abolition in Relation With Primary Insufficiency of Great Saphenous Veins (GSV) Using High Intensity Focused Ultrasound (HIFU) Generated by Sonovein: A Multi Center Prospective Pivotal Study

This is a multi-center series assessment with a planned accrual of 70 patients with diagnosed symptomatic primary GSV insufficiency. Patients will be consented at a Pre-Study Visit and evaluated for eligibility and for baseline characteristics of the disease. Patients will receive treatment with Sonovein for the targeted segments of GSV. At follow-up visits at 7 days (1 to 10 days), 3 months (+/- 20 days), 6 months (+/- 25 days), and 12 months (+/- 30 days) changes in veins and flow characteristics will be evaluated by ultrasound, and patient well-being, including pain which will be evaluated by patient-reported VAS evaluations. Continued follow-up for a total of 12 months will be completed prior to subject study exit. Adverse events (AE) will be assessed at every study visit following HIFU treatment.


Eligibility Criteria:
Inclusion Criteria:

* Candidate for venous procedure with primary GSV insufficiency involving reflux in the segment to be treated
* CEAP-clinical classification ≥ 2
* Physical condition allowing ambulation after the procedure.
* Agree to comply with the Clinical investigation plan and follow-up schedule of the study
* Targeted tissue reachable for treatment with the device.
* Age over 22 years at the time of enrollment.
* No acute venous thrombosis.
* No complete or near complete deep vein post-thrombotic disease.
* Patient has signed and understood the written informed consent.

Exclusion Criteria:

* Patient is pregnant
* Known allergic reaction to anesthetics to be used.
* Legally incapacitated or imprisoned patients
* Patient's vein target not clearly visible on the ultrasound images (in B mode) at the inclusion visit
* Patient participating in another clinical trial involving an investigational drug or device.
* Ankle-brachial index \<7 (ABI)
* Undergoing active anticoagulant therapy within the last 6 months
* Diameter of the treated anatomical segment below ≤ 2mm \& above \> 20mm
* Patients where HIFU cannot be delivered to tissues where macro calcifications induce a significant shadow in the ultrasonic image
* Patients where EPack must be put in contact with an ulcer
* Patients with significant thick scars on the skin over the segment to be treated
* Security distance respected in regards of :

  * nerves \& bones
  * the surrounding vessels
* Patient who may not be considered as good candidates for treatment by the investigator outside the explicit exclusion criteria above listed
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment.

This is an open-label, pragmatic, randomized trial of approximately 1,204 adult patients hospitalized across 9 United States hospitals with the overarching goal of determining whether the optimal approach for the management of GN-BSI is (1) IV antibiotics for the duration of treatment or (2) initial IV antibiotics followed by early transition to oral antibiotics for the duration of treatment. Patients will be randomized in a 1:1 ratio to remain on IV antibiotics or transition to oral antibiotics as soon as possible after blood culture collection, but no more than 5 days later. The primary objective is to compare the Desirability of Outcomes Ranking (DOOR) distributions between patients with GN-BSI receiving IV antibiotic treatment only versus patients transitioned early to oral antibiotic treatment. The study hypothesis is that oral treatment will result in a more favorable DOOR distribution than IV treatment, likely as a result of differential adverse events and changes in Quality of Life (QoL) profiles.

Eligibility Criteria:
Inclusion Criteria:

* Adult (≥ 18 years) at the time of screening
* Hospitalized
* Identification of at least one Gram-negative organism in a blood culture
* Capable of providing written informed consent (includes through a legally authorized representative)
* Willingness to adhere to assigned study arm
* Capable and willing to complete a follow-up QoL interview (including through a legally authorized representative)

Exclusion Criteria:

* Unable to tolerate or absorb a course of oral antibiotics
* Actively receiving vasopressors
* Gram-negative organism not susceptible to any oral antibiotics
* Gram-negative organism not susceptible to any IV antibiotics
* Polymicrobial bloodstream infection

  * The following patients with polymicrobial infections remain eligible for enrollment: (1) more than one morphology or species of a gram-negative organism (except for Acinetobacter baumannii or Stenotrophomonas maltophilia), (2) a single positive blood culture with a common commensal organism (grown in addition to an Enterobacterales species or Pseudomonas aeruginosa
* Allergy or contraindication rendering no oral option or no IV option for therapy with the listed antibiotic agents.
* Anticipated duration of therapy greater than 14 days
* Central nervous system infection
* Absolute neutrophil count of \<500 cells/mL or anticipated to reduce to \<500 cells/mL during the antibiotic treatment course.
* Receiving hospice care
Clinical Trial of New Single-use Compact Intermittent Catheter

The study is a randomised, single-blinded, controlled crossover study. The total study duration for the individual subject will be between two days - two weeks, consisting of three site visits. Visits 0 and 1 can be performed on the same day. Visit 2 can be performed the day after visit 1. For visit 1 and 2, catheterizations will be performed in a hospital setting by a health care professional for bladder emptying assessment and collection of urine samples for haematuria assessment. A sub-group of subjects (all enrolled subjects at DK sites) will be asked to conduct a self-catheterization at visit 2 after hcp catheterization and evaluate discomfort and PVR.

The total study duration for the individual subject will be up to 14 days.


Eligibility Criteria:
Inclusion Criteria:

* Is Female
* Is at least 18 years of age and has full legal capacity
* Has signed an informed consent form
* Has used clean intermittent self-catheterisation (CISC) (CH12 or CH14) for at least one month up to inclusion
* Is using intermittent self-catheterisation for a minimum of 3 times per day for bladder emptying
* Has used a compact catheter 50% of the time (or more) for the last two weeks prior to entering the study
* Has the ability (assessed by investigator) and willingness to follow study procedures or is able to use a compact catheter assessed by investigator

Exclusion Criteria:

* Is participating in any other clinical study during this investigation
* Has previously participated in this study
* Has symptoms of urinary tract infection at time of inclusion, as judged by the investigator (if the patient recovers within the recruitment period, a second inclusion is allowed, under a different subject id)
* Is an individual with a history of - suspected to be - or showing signs of producing an excessive amount of mucus or large/clustered sediments or debris
* Has any known allergies towards ingredients in the investigational device
* Is pregnant
* Is breastfeeding
Impact of Surgical Theater's Patient Engagement

To evaluate usefulness of Surgical Theater's Patient Engagement 360VR platform in helping align patient expectations and improve patient satisfaction and understanding in spinal surgery consults.

Surgical Theater is a company that has developed a platform which can be used to describe and explain spinal surgery to patient before they undergo the procedure. The platform specifically implements data from the patient's own MRI and CT scans, creating a 3d reconstruction that can be seen through a virtual reality lens. This technology was developed to help clarify any concerns patient's may have before surgery, and help them better appreciate what will occur in the OR.

Surgical theater has FDA clearance for patient interaction and engagement. Our study is to take surgical theater into our clinics and, after a patient is defined as a surgical candidate, use surgical theater to provide spatial learning and comprehension through modeling so they better understand their surgical plan. Only the SRP system will be used for this study (Surgical Planner).

The intervention is showing surgical theater to patients identified for surgery in clinic routinely. Surgical theater will be offered to all patients offered surgery. No other changes in practice will be done.

Eligibility Criteria:
Inclusion Criteria:

1. Age range: 18-89.
2. Patients undergoing elective lumbar or cervical spine surgeries
3. Those who are receiving Surgical Theater consultation as part of their clinical care

Exclusion Criteria:

1. Age \<18 years
2. Non-elective surgery due to emergency, trauma
3. Patients undergoing correction for spinal deformities
Breast/Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy

To determine rate and severity of chemotherapy induced neuropathy in extremities treated with cold gloves and socks versus control extremities

This is a therapeutic study investigating the use of cryotherapy in the prevention of chemotherapy-induced peripheral neuropathy (CIPN) and associated nail toxicities. The therapeutic intervention will involve patients wearing an Elasto-Gel cold glove and sock on one hand and one foot (both on the right side or both on the left side). The patients will wear the glove and sock during each infusion of taxane chemotherapy.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed diagnosis of early stage breast cancer (stage I-III).
* Planned to receive treatment with either adjuvant or neo-adjuvant taxane-based chemotherapy.
* Age \> 18 years. There is no upper age limit for participation in this study.
* Patients may have received any of the following therapies: surgery, chemotherapy, hormones, biologics, or radiation.
* Prior chemotherapies are permitted, except with prior treatments with taxanes, vinca alcaloids, gemcitabine, eribulin, ixabepilone, platinum drugs)
* All patients will have given signed, informed consent prior to registration
* Patients must have a performance status of ECOG 0 or 1.

Exclusion Criteria

* Patients must not have received any prior taxane or platinum based chemotherapy.
* Patients must not have a history of peripheral neuropathy (regardless of cause).
* Patient must not have a history of Raynaud's disease.
* Patients with partial or complete limb amputations.
* Known hypersensitivity to cold
* Patient cannot be on the following medications: GABA analogues (such as Neurontin, lyrica), tricyclic antidepressants (such as amitriptyline or nortriptyline)
* As judged by the investigator, severe uncontrolled concurrent medical conditions, psychiatric illness or social condition that would limit compliance with study requirements.
* Evidence of any significant clinical disorder or laboratory finding that makes it undesirable for the subject to participant in the clinical trial
* Must not be pregnant or breast feeding
Androgen-Deprivation Therapy and Cardiovascular Risk: A Nationwide Population-based Cohort Study

The research focuses on the safety profile of androgen-deprivation therapy (ADT). The hypothesis is that safety issue, as regards to cardiovascular risk, is not homogenous across the spectrum of androgen-deprivation therapy modalities. Our study will encompass all ADT modalities including intermittent ADT.

ADT is a cornerstone therapy in prostate cancer management. Decisions about ADT should weigh improvements in cancer-specific outcomes against potential increased risks for cardiovascular diseases. The potential for harm from ADT should be more precisely defined according to the type of ADT. Those potential risks underscore the importance of better understanding benefits of ADT, especially in contexts where data are still lacking.ADT is also indicated in sexually deviant behavior.

Our study is a nationwide population-based prospective cohort on 4 years thanks to the French Health Reimbursement Agency database (Système National d'Information Inter-Régimes de l'Assurance Maladie, SNIIRAM) and French hospital discharge database (Programme de Médicalisation des Systèmes d'Information; PMSI). A unique civil registration number has been assigned to all French residents and this number unambiguously links those two databases.

Eligibility Criteria:
Inclusion Criteria:

* Adults men, age greater 18 years,
* Affiliation to French Health System,
* Diagnosis of prostate cancer
* At least one dispensation (leading to a reimbursement claim) in a 1.5 year period of an androgen-deprivation therapy or a hospitalization for orchiectomy.

Exclusion Criteria:

* Orchiectomy for another reason that prostate cancer.
* Patients treated with both Gonadotropin Releasing Hormone agonists and bilateral orchiectomy will be excluded from analyses.
Pharmacokinetics and Safety Between "DWJ1421" and "DWC201903" in Healthy Male Volunteers

This is a randomized, open label, single dose, crossover study to compare the pharmacokinetics and safety between "DWJ1421" and "DWC201903" in healthy male volunteers.


Eligibility Criteria:
Inclusion Criteria:

* Between 19 aged and 45 aged in healthy male adult
* Body weight more than 50kg
* Body Mass Index more than 18.0 and under 27.0

Exclusion Criteria:

* Those who have clinical significant liver, kidney, digestive system, respiratory, endocrine, nervous system, hematology and oncology, cardiovascular, urinary diseae or past history
* Those who have a gastrointestinal disease history that can effect drug absorption or surgery
* Those who have hypersensitivity reaction or clinically significant hypersensitivity reaction in the history of Investigational product
Effects of Vitamin B12 Treatment in Singers

In this study, the investigators aim to assess if vitamin B12 treatment demonstrates a beneficial effect on voice performance. If so, they wish to examine the relationship between the vitamin B12 treatment and the study participant's general well-being.

Through the investigators' experience, they have observed that amongst singers and voice professionals, there is a common belief that there are voice benefits from cobalamin treatment. Consequently, some singers and voice professionals tend to ask for cobalamin injections in order to enhance their vocal performance. However, there are no previous reports that illustrate the effects of vitamin B12 deficiency or treatment on voice performance.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18 to 65 years old
* An active singer who is presently singing
* Willing and able to comply with the study requirements
* Completed and signed an informed consent form.

Exclusion Criteria:

* Known vitamin B12 deficiency
* Active or recent vitamin B12 treatment (the subject must not receive vitamin B12 treatment for at least 4 weeks)
* Any known bleeding disorder
* Any known laryngeal pathology
* Plans to start any new treatment, oral/parenteral anticoagulant, supplement, or medication during the study period
* Scored above the highest 10 percentile of performance in all three voice evaluation questionnaires will be withdrawn from the study before the first injection (i.e., scored less than or equal to 7 in the Voice Fatigue Index (VFI), less than or equal to 6 in the Evaluation of the Ability to Sing Easily (EASE), and less than or equal to 4 in the Singing Voice Handicap Index 10 (SVHI-10))
Electroencephalogram and Attention Deficit Hyperactivity Disorder Study

The purpose of this research is to assess and determine brain oscillations or "brain signatures" of adult participants with Attention Deficit Hyperactivity Disorder (ADHD) relative to adult participants without ADHD using the technique electroencephalogram (EEG). Electroencephalogram is entirely non-invasive way of tracking brain activity.The main goal of this study is to establish biological factors for determining the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD).


Eligibility Criteria:
Inclusion Criteria for all:

* Right-handedness

Inclusion Criteria for Attention Deficit Hyperactivity Disorder (ADHD) group:

* Currently unmedicated adults with ADHD. To be given a full diagnosis of adult ADHD, the participant must have full Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-R) criteria: (1) described a chronic course of ADHD symptomatology from childhood to adulthood, and (2) endorsed a moderate or sever level of impairment attributed to the ADHD symptoms.

Exclusion Criteria for all:

* Currently taking psychoative medications
* Any clinically significant neurological problem (e.g., tics, seizures, serious head injury)
* Alcohol or substance abuse (current or in the past 2 years)
* Any current Axis I psychiatric diagnosis (other than ADHD) as verified by clinical interview
Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs

* Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. It is one of the main causes of chronic liver diseases worldwide .
* According to World Health Organization (WHO), 2011 , Egypt has particularly high rates of Hepatitis C (22%).
* Hepatitis C virus (HCV) is known to induce both hepatic and extra-hepatic manifestations. About 17% of HCV patients present with at least one skin manifestation, which can be directly or indirectly induced by chronic HCV infection .

* Skin diseases which are certainly related with chronic HCV infection are mixed cryoglobulinemia, lichen planus , porphyria cutanea tarda, Chronic pruritus and necrolytic acral erythema; conditions that may share a possible association with HCV infection .
* while several immune-mediated inflammatory skin conditions, such as psoriasis, chronic urticaria and vitiligo, have been only rarely reported in the setting of chronic HCV infection .
* Peginterferon based regimen with or without ribavirin were the mainstay of HCV treatment with a cure rate of about 50%, Although these regimens were lengthy, complex, had significant side-effects and high failure rates .
* They also had higher rate of exacerbated dermatologic conditions such as discoid lupus, psoriasis and Lichen planus .
* Recently, Newer all-oral anti viral drugs regimens began to be approved for use in 2014. These regimens, involve one pill daily for 12 weeks, they have achieved sustained virologic response of over 90% and have more tolerable side effect profiles.
* Recently, The European Association for Study of Liver (EASL) 2015, American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) have now recommended that all chronically infected HCV patient should be offered treatment with new oral antiviral drugs .

Eligibility Criteria:
Inclusion Criteria:

1. Patients with HCV infection eligible for treatment with new (DAADs) and having:

   A- Normal Complete Blood Count ( hemoglobin not less than 10 gm/dl ). B- Mild to moderate impairment of Liver function test and kidney function test.

   C- Positive polymerase chain reaction for HCV virus. D- Controlled Blood sugar .
2. Patients \> 18 years

Exclusion Criteria:

1. Patients on treatment for skin disease.
2. Pregnancy and lactation.
3. Patients \<18 years.
4. Patients not eligible for oral anti hepatitis C drugs.
Online Ultrasound Curriculum on Learning Outcomes of Post-graduate Physicians

This single-center retrospective study evaluates the effectiveness of the Training Management System (TMS) ultrasound curriculum on the learning outcomes of PGY emergency physicians. By analyzing test scores and course participation data from 2018 to 2025, the study investigates whether blended learning improves PoCUS proficiency and explores its potential role in enhancing ultrasound education for junior physicians.

Current point-of-care ultrasound education faces multiple challenges. Traditional teaching methods, such as didactic lectures and bedside one-on-one training, are constrained by time, clinical workload, and faculty availability, leading to inconsistent learning outcomes. Additionally, PGY physicians, due to their limited clinical experience, struggle to develop proficiency in ultrasound in a randomized learning environment. The quality of ultrasound image acquisition and diagnostic accuracy is also highly dependent on the operator's experience. In recent years, online learning platforms, such as the Training Management System, have been introduced to enhance learning flexibility. However, the long-term impact of such platforms on trainees' clinical application remains unclear. This study aims to evaluate the impact of the TMS ultrasound curriculum on the learning outcomes of PGY emergency physicians and explore the feasibility of a blended learning approach in improving ultrasound skill application. This single-center retrospective study analyzes test data from PGY trainees who participated in emergency PoCUS training between 2018 and 2025, including post-course test scores, objective structured clinical examination scores, and self-reported TMS course participation. The findings of this study may provide insights into the effectiveness of online and blended learning models in developing ultrasound proficiency among junior physicians and inform future medical education curriculum design.

Eligibility Criteria:
Inclusion Criteria:

1. PGY trainees who participated in the Department of Emergency Medicine ultrasound training program during the study period.
2. Trainees with complete course participation records and assessment results.

Exclusion Criteria:

1. Non-PGY participants (e.g., senior residents, attending physicians, medical students).
2. Incomplete assessment data that prevents a full evaluation of learning outcomes.
3. Any abnormal data not meeting study criteria (e.g., recording errors or duplicate entries).